Quantum-Si Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Audio By Carbonatix

BRANFORD, Conn.--(BUSINESS WIRE)--Aug 13, 2025--

Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics technology company redefining protein analysis through single-molecule detection, today announced that the Compensation Committee of Quantum-Si’s Board of Directors has granted 237,068 restricted stock units (“RSUs”) to new employees under the Company’s previously adopted Quantum-Si Incorporated 2023 Inducement Equity Incentive Plan, as amended (the “2023 Inducement Plan”). The RSUs were granted as an inducement material to the new employees becoming an employee of Quantum-Si in accordance with Nasdaq Listing Rule 5635(c)(4).

The 2023 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Quantum-Si (or following a bona fide period of non-employment), as an inducement material to such individuals entering into employment with Quantum-Si, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.

The RSUs will vest 25% on September 20, 2026, with the remainder vesting in 12 equal quarterly installments thereafter, subject to the employee’s continued employment with Quantum-Si on such vesting dates. The RSUs are subject to the terms and conditions of the 2023 Inducement Plan and a RSU agreement covering the grant.

About Quantum-Si Incorporated

Quantum-Si is transforming proteomics with a benchtop platform that brings single-molecule protein analysis to every lab, everywhere. The Company’s platform enables real-time kinetic-based detection and allows researchers to move beyond traditional, multistep workflows and directly access dynamic, functional protein insights with unparalleled resolution. By making protein analysis simpler, faster, and more informative, Quantum-Si is accelerating proteomic discoveries to improve the way we live. Learn more at quantum-si.com or follow us on LinkedIn or X.

View source version on businesswire.com:https://www.businesswire.com/news/home/20250813611402/en/

CONTACT: Investor and Media

Jeff Keyes

Chief Financial Officer

[email protected]

KEYWORD: UNITED STATES NORTH AMERICA CONNECTICUT

INDUSTRY KEYWORD: ONCOLOGY HEALTH HEALTH TECHNOLOGY RESEARCH SCIENCE PHARMACEUTICAL BIOTECHNOLOGY

SOURCE: Quantum-Si Incorporated

Copyright Business Wire 2025.

PUB: 08/13/2025 04:05 PM/DISC: 08/13/2025 04:04 PM

http://www.businesswire.com/news/home/20250813611402/en